{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/","result":{"pageContext":{"chapter":{"id":"a3632aab-62ce-5263-b365-24e12194e389","slug":"progestogen-only-injectables","fullItemName":"Scenario: Progestogen-only injectables","depth":2,"htmlHeader":"<!-- begin field 7159ff3d-cb03-49ce-8c1b-71745fbe4b74 --><h2>Scenario: Progestogen-only injectables</h2><!-- end field 7159ff3d-cb03-49ce-8c1b-71745fbe4b74 -->","summary":"Covers the use of the progestogen-only injectable, including the available products; when to start it; the efficacy; how to manage common problems (such as late injection); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception.","htmlStringContent":"<!-- begin item e7d7effc-a899-443e-b0ea-ebe514f83746 --><!-- begin field d0c34053-a3f4-455f-94c6-acbc015798d1 --><p>From age 13 years to 60 years (Female).</p><!-- end field d0c34053-a3f4-455f-94c6-acbc015798d1 --><!-- end item e7d7effc-a899-443e-b0ea-ebe514f83746 -->","topic":{"id":"9ff99c6b-985a-5146-8ef5-665fc2b551bb","topicId":"832bfe6c-0c1e-4dca-89eb-7e914cf17833","topicName":"Contraception - progestogen-only methods","slug":"contraception-progestogen-only-methods","lastRevised":"Last revised in November 2019","chapters":[{"id":"e97a1889-5b3c-51c7-abca-435669821908","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9d1ba26b-0889-5782-a5dd-876d8d8965c8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e40c82f2-3cbd-56c2-b06f-b2d3bfae8a34","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3d3ddcb9-bbef-5443-9762-08bf7c296da4","slug":"changes","fullItemName":"Changes"},{"id":"5c8ed192-6ffb-5084-a621-3d1b14ea264d","slug":"update","fullItemName":"Update"}]},{"id":"c2b04259-e45f-54ea-ba94-5bc43975229b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c2cce341-0179-531a-bea7-9b8f9120b8c0","slug":"goals","fullItemName":"Goals"},{"id":"8aa31475-0c4c-5b7a-bbb7-82a288b1541c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"59f5527f-5091-5084-ab85-34cd87ab3424","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"14b43b64-8b02-5470-a6a1-41982cbed802","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1cd2c043-e2cd-5c97-9a82-32c5baf9f590","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"71e31498-8434-55e9-9802-459d2ed956f5","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"62d7d86a-7652-51fb-972e-f8113766a58c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ba99afb9-717a-59e6-b0af-a6fe316f6e0b","slug":"where-to-get-progestogen-only-contraception","fullItemName":"Where to get progestogen-only contraception"}]},{"id":"74f87f5c-2983-599c-9881-ad5d663100c0","fullItemName":"Management","slug":"management","subChapters":[{"id":"28c180bd-05b7-5bf7-8601-f61802a3f2b0","slug":"progestogen-only-pill","fullItemName":"Scenario: Progestogen-only pill"},{"id":"4c571c2d-718a-5351-ba2b-f3c8d69a15c4","slug":"progestogen-only-implant","fullItemName":"Scenario: Progestogen-only implant"},{"id":"a3632aab-62ce-5263-b365-24e12194e389","slug":"progestogen-only-injectables","fullItemName":"Scenario: Progestogen-only injectables"}]},{"id":"b040c0e0-cf32-51f5-8b09-18bca20a90c8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0b3c54f3-29e8-5d1b-af69-397a9b27760f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"654d1af0-9c4c-5d0a-90e6-d8cd8063b1c6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b1383200-8981-5368-ba45-a0d6bbbe92a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"05903434-c83e-5971-964b-85a3d8d7e8b3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3f865d6-8f60-5c7a-b522-6e18d274c84c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"39d2eca9-efb9-5f08-b73b-15fb2a3d4896","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d93103c6-16a2-5c1d-92ce-7a991173c791","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"74f87f5c-2983-599c-9881-ad5d663100c0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ebf464c5-dfe9-5c75-bc1f-561dad28505b","slug":"starting-a-progestogen-only-injectable","fullItemName":"Starting a progestogen-only injectable","depth":3,"htmlHeader":"<!-- begin field 1a25efb8-c65d-46d0-b422-995cd9890527 --><h3>Starting a progestogen-only injectable</h3><!-- end field 1a25efb8-c65d-46d0-b422-995cd9890527 -->","summary":null,"htmlStringContent":"<!-- begin item a556afec-3336-4df8-a7c5-232767581d73 --><!-- end item a556afec-3336-4df8-a7c5-232767581d73 -->","subChapters":[{"id":"a5e147c7-9466-537c-a105-6f40c20a822d","slug":"assessment","fullItemName":"Assessment","depth":4,"htmlHeader":"<!-- begin field a6660859-b94c-4c3a-9b7f-a7a700e6f8f6 --><h4>How should I assess a woman before providing her with a progestogen-only injectable?</h4><!-- end field a6660859-b94c-4c3a-9b7f-a7a700e6f8f6 -->","summary":null,"htmlStringContent":"<!-- begin item 12944b02-6d71-4864-9d25-a7a700e6f605 --><!-- begin field d7982d25-3fd0-4128-8bc3-a7a700e6f8f6 --><ul><li>For information on assessing a woman considering starting a progestogen-only injectable, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/management/assessment-for-specific-contraceptive-methods/#progestogen-only-injectable\">Progestogen-only injectable</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul><!-- end field d7982d25-3fd0-4128-8bc3-a7a700e6f8f6 --><!-- end item 12944b02-6d71-4864-9d25-a7a700e6f605 -->","subChapters":[]},{"id":"fbf5d04b-615c-59e3-8eb1-e81f6645c8e0","slug":"when-to-start","fullItemName":"When to start","depth":4,"htmlHeader":"<!-- begin field 7ba89ea9-25ab-432a-8656-5a3f1a1bde63 --><h4>When should I start a progestogen-only injectable?</h4><!-- end field 7ba89ea9-25ab-432a-8656-5a3f1a1bde63 -->","summary":null,"htmlStringContent":"<!-- begin item 08c75333-5285-48ff-8192-f303c4aa83af --><!-- begin field 6ebe6b3c-8bb7-4f01-8cdb-30b706a6f969 --><ul><li><strong>If the woman is not currently using a regular method of contraception:</strong><ul><li>Ideally, give the first injection up to, and including day 5 after the start of menstrual bleeding. <ul><li>No additional contraception is required.</li></ul></li><li>If this is not possible, give the progestogen-only injectable at any other time in the menstrual cycle provided it is reasonably certain that the woman is not pregnant and there is no risk of conception.<ul><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong>If the woman is starting the injectable after oral emergency contraception:</strong><ul><li>Ideally offer a bridging method of contraception (such as combined hormonal contraception or progestogen-only pills) until pregnancy can be excluded. However if this is not suitable or acceptable:<ul><li>For levonorgestrel, give the progestogen-only injectable and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li><li>For ulipristal acetate, give the injection 5 days after taking ulipristal acetate, and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li><li>Advise the woman to take a pregnancy test no sooner than 3 weeks after the most recent episode of unprotected sexual intercourse (UPSI).</li></ul></li><li><strong>If the woman is changing from a combined hormonal contraceptive (CH</strong><strong>C</strong>):<ul><li>Give the progestogen-only injectable on day 1 of the hormone-free interval.<ul><li>No additional contraception is required.</li></ul></li><li>If the injection is given on week 1 of normal CHC use: <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days. </li><li>If UPSI has occurred after day 3 of the hormone-free interval, advise the woman to restart the CHC method for at least 7 days.</li></ul></li><li>If the injection is given on weeks 2–3 of normal CHC use: <ul><li>No additional contraception is required if the CHC method has been used consistently and correctly for the previous 7 days.</li></ul></li></ul></li><li><strong>If the woman is changing from the progestogen-only pill (POP) or </strong><strong>levonorgestrel intrauterine system (LNG-IUS):</strong><ul><li>The progestogen-only injectable can be given at any time in the menstrual cycle.</li><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days, or continue the existing method for 7 days, regardless of when in the menstrual cycle the injection is given.</li></ul></li><li><strong>If the woman is changing from another injectable progestogen-only contraceptive:</strong><ul><li>Give the progestogen-only injectable on or before the day the next injection is due.<ul><li>No additional contraception is required.</li></ul></li></ul></li><li><strong>If the woman is changing from a progestogen-only implant:</strong><ul><li>Give the progestogen-only injectable up to 3 years after insertion of the implant.<ul><li>No additional contraception is required.</li></ul></li><li>If the injection is given more than 3 years after insertion of the implant: <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days after the injection.</li><li>Consider the need for emergency contraception or a pregnancy test (no sooner than 3 weeks after the most recent UPSI) if pregnancy cannot be excluded. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-emergency/\">Contraception - emergency</a>.</li></ul></li></ul></li><li><strong>If the woman is changing from a barrier method of contraception (such as condoms), or a copper </strong><strong>intrauterine device (Cu-IUD):</strong><ul><li>Give the progestogen-only injectable on day 1–5 of the menstrual cycle.<ul><li>No additional contraception is required.</li></ul></li><li>If the progestogen-only injectable is given at any other time in the menstrual cycle:<ul><li>Advise the woman to abstain from sex for 7 days, or continue the existing method for at least 7 days.</li></ul></li></ul></li></ul><!-- end field 6ebe6b3c-8bb7-4f01-8cdb-30b706a6f969 --><!-- end item 08c75333-5285-48ff-8192-f303c4aa83af -->","subChapters":[]},{"id":"723b5ce3-d516-520a-bd53-5e7f79b71282","slug":"types-of-progestogen-only-injectable","fullItemName":"Types of progestogen-only injectable","depth":4,"htmlHeader":"<!-- begin field 0aa2b551-04df-4ae0-ac34-6753f56416c4 --><h4>What types of progestogen-only injectables are available?</h4><!-- end field 0aa2b551-04df-4ae0-ac34-6753f56416c4 -->","summary":null,"htmlStringContent":"<!-- begin item 428c7862-cae3-4c26-b957-694cc2eada54 --><!-- begin field ccc6cb79-7685-4676-9599-7de2c0b2a81a --><ul><li>Three progestogen-only injectables are currently available in the UK:</li><ul><li>Depot medroxyprogesterone acetate 150 mg (Depo-Provera®) is the most commonly used progestogen-only injectable and is licensed for long-term use.</li><ul><li>It is given every 12 weeks by deep intramuscular injection.</li></ul><li>Depot medroxyprogesterone acetate 104 mg (Sayana Press®) is also licensed for long-term use.</li><ul><li>It is given every 13 weeks by subcutaneous injection.</li><li>Women may self-administer Sayana Press® after the first injection once they have received training in injection technique and the administration schedule from a healthcare professional.</li></ul><li>Norethisterone enantate, 200 mg (Noristerat®) is rarely used and is only licensed for short-term use (two injections).</li><ul><li>It is given every 8 weeks apart by deep intramuscular injection.</li></ul></ul></ul><!-- end field ccc6cb79-7685-4676-9599-7de2c0b2a81a --><!-- end item 428c7862-cae3-4c26-b957-694cc2eada54 -->","subChapters":[]},{"id":"b821aadc-1d6b-56f5-baea-692aa51a1154","slug":"mechanism-of-action","fullItemName":"Mechanism of action","depth":4,"htmlHeader":"<!-- begin field f247c8e3-8aa3-4ac7-bf02-c3f92fddcafd --><h4>How do progestogen-only injectables work?</h4><!-- end field f247c8e3-8aa3-4ac7-bf02-c3f92fddcafd -->","summary":null,"htmlStringContent":"<!-- begin item 3869a665-936a-4e5b-9a6a-c8cdd6978a0d --><!-- begin field 247ebe23-1759-4892-8f5b-42bd8160350b --><ul><li>Progestogen-only injectables (depot medroxyprogesterone acetate and norethisterone enantate) prevent pregnancy by the inhibition of ovulation and thickening of the cervical mucus, thereby presenting a barrier for sperm penetration.</li><li>In addition, changes to the endometrium make it an unfavourable environment for implantation.<br></li></ul><!-- end field 247ebe23-1759-4892-8f5b-42bd8160350b --><!-- end item 3869a665-936a-4e5b-9a6a-c8cdd6978a0d -->","subChapters":[]},{"id":"65afd4b4-c054-542e-8d5f-4fe72b6487fd","slug":"choice-of-progestogen-only-injectable","fullItemName":"Choice of progestogen-only injectable","depth":4,"htmlHeader":"<!-- begin field e4362b54-90e4-434c-b201-a6ce00af5f44 --><h4>Which progestogen-only injectable should I recommend?</h4><!-- end field e4362b54-90e4-434c-b201-a6ce00af5f44 -->","summary":null,"htmlStringContent":"<!-- begin item 9fba6195-a662-49f6-b7d7-a6ce00af5d6a --><!-- begin field db90c412-b3ca-4a82-b4d2-a6ce00af5f44 --><ul><li>If the woman requires contraception for only a few months (short-term use), consider either:<ul><li>Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®), <em>or</em></li><li>Norethisterone enantate (Noristerat®).</li></ul></li><li>If the woman requires long-term contraception, consider:<ul><li>Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®).<ul><li>Women may self-administer Sayana Press® after the first injection once they have received training in injection technique and the administration schedule from a healthcare professional.</li></ul></li></ul></li></ul><!-- end field db90c412-b3ca-4a82-b4d2-a6ce00af5f44 --><!-- end item 9fba6195-a662-49f6-b7d7-a6ce00af5d6a -->","subChapters":[]},{"id":"2a3823fe-f8ed-5649-8f1b-8097f5839942","slug":"when-to-start-amenorrhoea","fullItemName":"When to start - Amenorrhoea","depth":4,"htmlHeader":"<!-- begin field aa5cb51e-4a57-4a58-8039-a6ce00b1a663 --><h4>Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</h4><!-- end field aa5cb51e-4a57-4a58-8039-a6ce00b1a663 -->","summary":null,"htmlStringContent":"<!-- begin item 4eb63584-fbfa-4146-ab34-a6ce00b1a412 --><!-- begin field 62c66409-ccb4-46b5-b0f4-a6ce00b1a663 --><ul><li><strong>If the woman is amenorrhoeic:</strong><ul><li>Give the progestogen-only injectable at any time if it is reasonably certain the woman is not pregnant. <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong>If the woman is postpartum (whether breastfeeding or not):</strong><ul><li>Give the progestogen-only injectable before day 21 postpartum:<ul><li>No additional contraception is required.</li></ul></li><li>If the progestogen-only injectable is given on or after day 21 postpartum:<ul><li>Advise the woman to avoid sex or use a barrier method of contraception (such as condoms) for 7 days, unless menstruation has started and the injection has been given on days 1–5.</li></ul></li></ul></li><li><strong>If the woman has had a miscarriage or termination of pregnancy:</strong><ul><li>If gestation is less than 24 weeks, ideally give the progestogen-only injectable immediately after a miscarriage, surgical termination, or the first part of a medical termination.<ul><li>If the progestogen-only injectable is given within 5 days of miscarriage or termination, no additional contraception is required.</li><li>If the progestogen-only injectable is given more than 5 days after miscarriage or termination, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li><li>If gestation is 24 weeks or more, treat as for a woman who is postpartum.</li></ul></li></ul><!-- end field 62c66409-ccb4-46b5-b0f4-a6ce00b1a663 --><!-- end item 4eb63584-fbfa-4146-ab34-a6ce00b1a412 -->","subChapters":[]},{"id":"9a6d0f74-cf83-5389-8419-9459ab40fc04","slug":"basis-for-recommendation-272","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1c4a3b76-263b-45b6-9c6e-a7a700e7d993 --><h4>Basis for recommendation</h4><!-- end field 1c4a3b76-263b-45b6-9c6e-a7a700e7d993 -->","summary":null,"htmlStringContent":"<!-- begin item 272525d0-0e4a-48e8-816d-a7a700e7d7dc --><!-- begin field 687a99cf-474a-40d5-a523-a7a700e7d993 --><h5>Types of progestogen-only injectable</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>] and the manufacturers' Summaries of Products Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016e</a>].</li></ul><h5>Mechanism of action</h5><ul><li>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul><h5>When to start</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>], and <em>Contraception after pregnancy </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2017b</a>], the <em>UK Medical Eligibility Criteria</em> <em>for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2016</a>], a statement from the FSRH clinical effectiveness unit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2015b</a>], and the manufacturers' Summaries of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016e</a>].</li></ul><h5>Progestogen-only injectable use in breastfeeding women</h5><ul><li>The FSRH advises that the progestogen-only injectable can be given on day 21 postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2016</a>].</li><li>However the manufacturers advise that it is given no sooner than 6 weeks postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016e</a>].</li></ul><!-- end field 687a99cf-474a-40d5-a523-a7a700e7d993 --><!-- end item 272525d0-0e4a-48e8-816d-a7a700e7d7dc -->","subChapters":[]}]},{"id":"26a1d69c-1a22-56f9-bc56-ce5962d3535d","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field f5bc01c7-0cb4-478a-9e95-edfecb475f30 --><h3>What information and advice should I give a woman who is considering using a progestogen-only injectable?</h3><!-- end field f5bc01c7-0cb4-478a-9e95-edfecb475f30 -->","summary":null,"htmlStringContent":"<!-- begin item 51bb649c-7cee-4594-b44f-b752f11514df --><!-- begin field b60a1996-2922-486d-8420-4bc58f43cf77 --><ul><li><strong>Discuss:</strong><ul><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#mechanism-of-action\">mechanism of action</a> of the progestogen-only injectable.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#advantages-disadvantages\">advantages, disadvantages, and risks</a> of the progestogen-only injectable.</li><li>The <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#efficacy\">efficacy</a> of the progestogen-only injectable.</li><li>What happens when the progestogen-only injectable is stopped.<ul><li>Advise the woman that there could be a delay of up to 1 year in the return of normal fertility. Menstruation can take several months to return to normal.</li></ul></li></ul></li><li><strong>Give advice on:</strong><ul><li>The possible <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#risks-adverse-effects\">adverse effects</a> (such as <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#risks-adverse-effects\">menstrual irregularities</a>) of the progestogen-only injectable. </li><li>How to manage a <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#late-repeat\">late repeat</a> of the injection.</li><li>The link between <em>Human papilloma viru</em>s (HPV) and cervical cancer, as well as strategies to reduce that risk. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a>.</li><li>The need for routine cervical cytology screening. </li><li>The possibility of <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#drug-interactions\">drug interactions</a>.</li></ul></li><li><strong>Also provide written information on the progestogen-only injectable.</strong><ul><li>The Family Planning Association provides a useful leaflet with information for users of the <a href=\"http://www.fpa.org.uk/sites/default/files/contraceptive-injections-your-guide.pdf\" data-hyperlink-id=\"e939164b-7e8f-44ba-a598-a93100b9e5dd\">progestogen-only injectable</a>. </li></ul></li></ul><!-- end field b60a1996-2922-486d-8420-4bc58f43cf77 --><!-- end item 51bb649c-7cee-4594-b44f-b752f11514df -->","subChapters":[{"id":"702818e7-3228-5ca2-a466-ef3f02fb22d3","slug":"late-repeat","fullItemName":"Late repeat","depth":4,"htmlHeader":"<!-- begin field 0dc3cf97-a4ad-44c6-8584-a7a700e875e8 --><h4>What should I do if the repeat injection is late?</h4><!-- end field 0dc3cf97-a4ad-44c6-8584-a7a700e875e8 -->","summary":null,"htmlStringContent":"<!-- begin item ce9b66df-aaf5-4413-92a9-a7a700e873b4 --><!-- begin field 4fce2837-95a3-4006-b419-a7a700e875e8 --><ul><li><strong>If it has up to </strong><strong>14 weeks since the last injection</strong><strong> of depot medroxyprogesterone or 10 weeks for norethisterone enantate was given</strong>:<ul><li>Give the repeat injection.</li><li>No additional contraception is needed.</li></ul></li><li><strong>If it has been more than 14 weeks since the the last injection of depot medroxyprogesterone or 10 weeks for norethisterone enantate was given </strong><strong>and:</strong><ul><li>Unprotected sexual intercourse (UPSI) has occurred within the last 5 days:<ul><li>Offer emergency contraception. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-emergency/\">Contraception - emergency</a>.</li><li>Bridging methods such as progestogen-only pills (POPs) or combined hormonal contraception (CHC) are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. F</li></ul></li><li>UPSI has occurred more than 5 days ago <em>and</em> within the last 5 days: <ul><li>Offer oral emergency hormonal contraception.</li><li>Bridging methods such as POPs or CHC are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li><li>UPSI has occurred more than 5 days ago, but within the last 3 weeks:<ul><li>Do not offer emergency contraception.</li><li>Bridging methods such as POPs or CHC are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li><li>UPSI has occurred more than 3 weeks ago:<ul><li>Do not offer emergency contraception.</li><li>Perform a pregnancy test, and administer the progestogen-only injectable if this is negative.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days.</li></ul></li></ul></li><li><strong>If the timing of the previous depot medroxyprogesterone acetate injection is unknown</strong><ul><li>Repeat the injection, provided it is reasonably certain that the woman is not pregnant.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for 7 days after the injection.</li></ul></li></ul><!-- end field 4fce2837-95a3-4006-b419-a7a700e875e8 --><!-- end item ce9b66df-aaf5-4413-92a9-a7a700e873b4 -->","subChapters":[]},{"id":"abb683d1-ea9b-5c68-9d34-1a8d161cbc4a","slug":"pregnancy","fullItemName":"Pregnancy","depth":4,"htmlHeader":"<!-- begin field 9ea5753b-ab73-4563-9ee6-fd5e65bfe3f2 --><h4>How should I manage a woman who becomes pregnant whilst using the progestogen-only injectable?</h4><!-- end field 9ea5753b-ab73-4563-9ee6-fd5e65bfe3f2 -->","summary":null,"htmlStringContent":"<!-- begin item 91005fec-b157-498e-b9e8-337109081932 --><!-- begin field 7ffde608-11a1-4723-81f8-7d5899224c15 --><ul><li>If a woman is found to be pregnant whilst using the progestogen-only injectable, reassure her that there is no evidence of harm to the fetus or the mother.<br></li></ul><!-- end field 7ffde608-11a1-4723-81f8-7d5899224c15 --><!-- end item 91005fec-b157-498e-b9e8-337109081932 -->","subChapters":[]},{"id":"4b5c1325-a7b3-5f55-aecd-57071b5cf3a2","slug":"basis-for-recommendation-159","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e4df88db-977d-4dad-a803-a7a700e91276 --><h4>Basis for recommendation</h4><!-- end field e4df88db-977d-4dad-a803-a7a700e91276 -->","summary":null,"htmlStringContent":"<!-- begin item 15999f55-6f08-419c-af63-a7a700e910c3 --><!-- begin field 2b16ae3f-751b-4e56-ad5d-a7a700e91276 --><h5>Information and advice</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul><h5>Human papilloma virus and depot medroxyprogesterone (DMPA) injectable</h5><ul><li>There is a weak association between cervical cancer and use of DMPA for 5 years or longer. Any increased risk appears to reduce with time after stopping and could be due to confounding factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul><h5>Late repeat injection</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul><h5>Pregnancy</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>], the <em>UK Medical Eligibility Criteria</em> <em>for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2016</a>], and the manufacturers' Summaries of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016e</a>].</li><li>The manufacturers of Depo-Provera® and Sayana Press® state that infants born from accidental pregnancies that occur 1–2 months after injection may be at increased risk of low birth weight and neonatal death. <ul><li>However, this was based on one observational study (n = 1207) in Thailand, with many confounding factors.</li><li>The FSRH advises that there is no harm to the fetus or to the mother [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul></li></ul><!-- end field 2b16ae3f-751b-4e56-ad5d-a7a700e91276 --><!-- end item 15999f55-6f08-419c-af63-a7a700e910c3 -->","subChapters":[]}]},{"id":"b1a8c87b-afe3-52b8-96fa-63c366cf433f","slug":"advantages-disadvantages","fullItemName":"Advantages and disadvantages","depth":3,"htmlHeader":"<!-- begin field 4e6ef2d9-c4cc-4908-86c7-c7d06478b1e2 --><h3>What are the advantages and disadvantages of progestogen-only injectables?</h3><!-- end field 4e6ef2d9-c4cc-4908-86c7-c7d06478b1e2 -->","summary":null,"htmlStringContent":"<!-- begin item 2b5dc7d1-cade-4362-a83b-383728c0ba33 --><!-- begin field 2cefc7c3-b441-4ac7-ace6-bc72f2517fd6 --><p>This information relates primarily to depot medroxyprogesterone acetate (DMPA) and is assumed to apply to norethisterone enantate (NET-EN).</p><h4>Advantages</h4><ul><li>It is very <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#efficacy\">effective</a>.</li><li>Users do not have to think about contraception for as long as the injection lasts — 12 weeks for DMPA and 8 weeks for NET-EN.</li><li>Sex need not be interrupted to use contraception.</li><li>It can be used when breastfeeding.</li><li>There are no known interactions with any medications (including liver enzyme-inducing drugs).</li><li>It may reduce heavy painful periods and help with premenstrual symptoms.</li><li>It can be used in situations where combined hormonal contraceptives are not recommended. </li><li>It can be used by women with a body mass index (BMI) greater than 35 kg/m2 (but may cause further weight gain).</li><li>It may reduce the risk of ovarian and endometrial cancer.</li></ul><h4>Disadvantages</h4><ul><li>It is not rapidly reversible. After stopping use of progestogen-only injectables:<ul><li>There could be a delay of up to 1 year in the return of normal fertility.</li><li>Menstruation can take several months to return to normal.</li></ul></li><li>It does not protect against sexually transmitted infections (STIs).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#risks-adverse-effects\">Adverse effects</a> including unscheduled bleeding and weight changes may occur. </li></ul><!-- end field 2cefc7c3-b441-4ac7-ace6-bc72f2517fd6 --><!-- end item 2b5dc7d1-cade-4362-a83b-383728c0ba33 -->","subChapters":[{"id":"859d7a0f-7232-5a5c-98c9-982d5f6bf73f","slug":"basis-for-recommendation-0b5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 004ed87c-8c34-4bc5-a3ed-760da429bd15 --><h4>Basis for recommendation</h4><!-- end field 004ed87c-8c34-4bc5-a3ed-760da429bd15 -->","summary":null,"htmlStringContent":"<!-- begin item 0b5535b5-e533-436f-b280-7e2d85d8aca2 --><!-- begin field c0827355-1f73-42e0-81f7-e2339b61ee0d --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>] and the National Institute for Heath and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">NICE, 2014</a>].</p><!-- end field c0827355-1f73-42e0-81f7-e2339b61ee0d --><!-- end item 0b5535b5-e533-436f-b280-7e2d85d8aca2 -->","subChapters":[]}]},{"id":"9abdd5b5-9bd8-5e34-aed4-2f0d64c31575","slug":"risks-adverse-effects","fullItemName":"Risks and adverse effects","depth":3,"htmlHeader":"<!-- begin field 9bef4325-0de0-4823-817a-fa8f6c46b6c5 --><h3>What are the possible risks and adverse effects of progestogen-only injectables?</h3><!-- end field 9bef4325-0de0-4823-817a-fa8f6c46b6c5 -->","summary":null,"htmlStringContent":"<!-- begin item 6a213420-3457-4e42-86e3-d552a22f2a96 --><!-- begin field 07f9e2d7-18dd-48c9-b6a4-db95df2af373 --><ul><li><strong>Menstrual irregularities </strong>— for more information,<strong> </strong>see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#menstrual-irregularities\">Unscheduled bleeding</a>.</li><li><strong>Weight gain </strong>— depot medroxyprogesterone acetate (DMPA) is associated with weight gain — up to 2–3 kg in weight over the first year of use.<ul><li>A higher initial body mass index (BMI) is predictive of weight gain in adolescents.</li><li>Women who experience a weight gain of more than 5% in the first 6 months are likely to experience continued weight gain.</li><li>If a woman using the progestogen-only injectable presents with a weight gain:<ul><li>Advise her that weight gain is common with DMPA use.</li><li>Exclude pregnancy.</li><li>Offer lifestyle advice (diet and exercise).</li></ul></li><li>If weight gain is severe, consider:<ul><li>Referring to a dietitian.</li><li>Investigating for other causes of severe weight gain (such as eating disorders, depression, or thyroid disease).</li></ul></li></ul></li><li><strong>Cancer risk</strong><ul><li>There is a possible increased risk of breast cancer. However, this risk is very small compared with the overall risk of developing breast cancer and gradually disappears within 10 years after stopping the progestogen-only injectable.<ul><li>For more information about the risks, which are the same as for progestogen-only pills, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#risks-adverse-effects\">Adverse effects</a> in the <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/\">Scenario: Progestogen-only pill</a>.</li></ul></li><li>There is a weak association between cervical cancer and use of DMPA for 5 years or longer. Any increased risk is reduced with time after stopping.<ul><li>Ensure women requesting DMPA are undergoing routine cervical screening.</li></ul></li></ul></li><li><strong>Effect on bone mineral density (BMD)</strong> — the use of DMPA is associated with a small loss of BMD with long-term use (more than 1 year). However, this is usually recovered after stopping the injection, and there is no evidence that DMPA increases the risk of fracture.<ul><li>If a woman wishes to use DMPA long-term, review the woman every 2 years to assess the risks and benefits of the injection and to decide whether treatment can be continued.</li><li>Consider other methods of contraception for:<ul><li>Women younger than 18 years of age (consider the DMPA injection only if all other methods of contraception are unsuitable or unacceptable).</li><li>Women with significant risk factors for osteoporosis (for example long-term corticosteroid use).<strong> </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li></ul></li></ul></li><li><strong>Injection site reactions</strong><ul><li>These are more common with subcutaneous (Sayana Press®) than intramuscular DMPA (Depo Provera®), and includes pain, abscess, and scarring.</li></ul></li><li><strong>There is little evidence that the use of the progestogen-only injectable causes the following reported adverse effects:</strong><ul><li>Mood changes.</li><li>Loss of libido.</li><li>Acne.</li><li>Headache.</li><li>Hot flushes</li><li>Vaginitis.</li></ul></li></ul><!-- end field 07f9e2d7-18dd-48c9-b6a4-db95df2af373 --><!-- end item 6a213420-3457-4e42-86e3-d552a22f2a96 -->","subChapters":[{"id":"3e33410e-b48f-5ada-80ae-2dca662f20d8","slug":"basis-for-recommendation-5e6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 74712257-354f-43ae-aa8b-485a2839e233 --><h4>Basis for recommendation</h4><!-- end field 74712257-354f-43ae-aa8b-485a2839e233 -->","summary":null,"htmlStringContent":"<!-- begin item 5e680cbf-48b4-4dfa-827f-41ecbab441ef --><!-- begin field 4be32b49-6744-488d-a933-3a9028f1ee5b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines, <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>] and <em>Problematic bleeding with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2015c</a>], and the National Institute for Heath and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">NICE, 2014</a>] and <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">NICE, 2015</a>].</p><h5>Progestogen-only injectables and cervical cancer risk</h5><ul><li>A pooled analysis from two case-control studies suggested a possible increased risk of cervical cancer with use for 5 years or more (RR 1.2, 95% CI 1.0–1.6) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li><li>A re-analysis of epidemiological data also found a small significant increased risk of invasive cervical cancer (RR 1.22, 95% CI 1.01–1.46) in women who had used depot medroxyprogesterone acetate (DMPA) for more than 5 (mean 8.8) years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</li></ul><!-- end field 4be32b49-6744-488d-a933-3a9028f1ee5b --><!-- end item 5e680cbf-48b4-4dfa-827f-41ecbab441ef -->","subChapters":[]},{"id":"f06e9ff8-4e9e-5da9-8e38-08a3a4667539","slug":"menstrual-irregularities","fullItemName":"Menstrual irregularities","depth":4,"htmlHeader":"<!-- begin field 4be4c212-ef4e-4db4-a80b-a6ce00b8d773 --><h4>How should I manage unscheduled bleeding in women using the progestogen-only injectable?</h4><!-- end field 4be4c212-ef4e-4db4-a80b-a6ce00b8d773 -->","summary":null,"htmlStringContent":"<!-- begin item e1e0ff97-bd98-40f2-9ebd-a6ce00b8d593 --><!-- begin field 463d7fd8-e289-457b-a74d-a6ce00b8d773 --><ul><li> <strong>Exclude or manage situations which could result in unscheduled bleeding</strong>, such as:<ul><li>Sexually transmitted infections (STIs) — as a minimum, test for <em>Chlamydia trachomatis</em>. The risk of STIs is increased if the woman is under 25 years, has a new sexual partner, or has had more than one sexual partner in the last year. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a>.</li><li>Pregnancy — perform a pregnancy test.</li><li>Gynaecological conditions such as cervical cancer — if this is suspected, refer women the woman using a suspected cancer pathway referral (for an appointment within 2 weeks). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li><li>Endometrial cancer — refer women aged 55 and older using a suspected cancer pathway referral (for an appointment within 2 weeks) if they have menstrual irregularities. Refer women younger than 55 years if they have risk factors for endometrial cancer and persistent, problematic bleeding after the first 3 months of use, or if they present with a change in bleeding pattern after at least 3 months of use.<br>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li><li>Drug interactions.</li></ul></li><li><strong> Consider performing a pelvic and speculum examination:</strong><ul><li>For persistent bleeding beyond the first 3 months of use — unscheduled bleeding is common in the first 3 months of starting a new hormonal contraceptive method.</li><li>For new symptoms or a change in bleeding after at least 3 months of use.</li><li>If the woman has not participated in the National Cervical Screening programme regularly. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-cancer-hpv/\">Cervical cancer and HPV</a>.</li><li>If requested by the woman.</li><li>If there are other symptoms such as pelvic pain, dyspareunia, or post coital bleeding. </li></ul></li><li>If no other underlying cause of irregular bleeding is suspected, and speculum and pelvic examination is normal, the bleeding can be assumed to be caused by the progestogen-only injectable.<ul><li>Reassure the woman that bleeding disturbances are common and that:<ul><li>Around 1 in 10 women may be amenorrhoeic in the first 3 months of use.</li><li>Rates of amenorrhoea increase with duration of use.</li><li>Around 50% or more of women are amenorrhoeic at 12 months.</li></ul></li><li>Continue with the injectable if the woman is happy to continue.</li></ul></li><li>However, if bleeding is problematic, consider treating with:<ul><li>A combined oral contraceptive (30–35 micrograms of ethinylestradiol with levonorgestrel or norethisterone) either cyclically or continuously for up to 3 months provided it is not contraindicated (off-label use). For more information, see the Scenario: Combined oral contraceptive pill in the CKS topic on Contraception - combined hormonal methods.</li><li>Mefenamic acid 500 mg two or three times a day (or tranexamic acid 1 g four times a day) for 5 days. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/prescribing-information/\">Prescribing information</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menorrhagia/\">Menorrhagia</a>.</li><li>Changing to another contraceptive method. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li><li>Be aware that: <ul><li>Some women experience prolonged amenorrhoea; this is most likely in older women and is usually acceptable to the woman.</li><li>Amenorrhea is more likely with depot medroxyprogesterone acetate (DMPA) than norethisterone enantate (NET-EN).</li><li>Irregular bleeding may continue for some months after stopping the injection.</li></ul></li><li>There is no evidence that reducing the injection interval for DMPA improves bleeding.</li></ul><!-- end field 463d7fd8-e289-457b-a74d-a6ce00b8d773 --><!-- end item e1e0ff97-bd98-40f2-9ebd-a6ce00b8d593 -->","subChapters":[]}]},{"id":"d57a5595-57a7-5cbd-b1eb-18feed31b5c0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 72c6667a-9a5e-4300-9a23-960bc77bf0d7 --><h3>What advice should I give regarding potential drug interactions with the progestogen-only injectable?</h3><!-- end field 72c6667a-9a5e-4300-9a23-960bc77bf0d7 -->","summary":null,"htmlStringContent":"<!-- begin item f628033b-6b0e-4d1f-a79c-251361b8b049 --><!-- begin field 7429cd7e-4600-4fdb-9ec4-802bb13280a9 --><ul><li>The efficacy of the progestogen-only injectable is not reduced by liver enzyme-inducing drugs. </li><li>Ulipristal acetate has the potential to reduce the efficacy of hormonal contraception.</li><ul><li>Advise women to start the progestogen-only injectable 5 days after taking ulipristal acetate and to use a barrier method of contraception (such as condoms) during this time and for the next 7 days. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-emergency/\">Contraception - emergency</a>.</li></ul></ul><!-- end field 7429cd7e-4600-4fdb-9ec4-802bb13280a9 --><!-- end item f628033b-6b0e-4d1f-a79c-251361b8b049 -->","subChapters":[{"id":"09bd71d2-01d5-58d1-b1c1-cde5641b03a1","slug":"basis-for-recommendation-095","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a2819043-0dca-4686-af80-bb319de70259 --><h4>Basis for recommendation</h4><!-- end field a2819043-0dca-4686-af80-bb319de70259 -->","summary":null,"htmlStringContent":"<!-- begin item 095fb170-bdc7-4f83-89b8-0a65e6e11908 --><!-- begin field f8cc9110-03c9-4c6f-aa8a-49ef6577ab50 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>], and <em>Drug interactions with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2012</a>], and a statement from the FSRH clinical effectiveness unit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2015b</a>].</p><!-- end field f8cc9110-03c9-4c6f-aa8a-49ef6577ab50 --><!-- end item 095fb170-bdc7-4f83-89b8-0a65e6e11908 -->","subChapters":[]}]},{"id":"98363f43-76a3-5783-bc6e-58199f6ef027","slug":"efficacy","fullItemName":"Efficacy","depth":3,"htmlHeader":"<!-- begin field 12786fe7-b4db-44f0-a8bb-5da4c4d26984 --><h3>How effective are progestogen-only injectables at preventing pregnancy?</h3><!-- end field 12786fe7-b4db-44f0-a8bb-5da4c4d26984 -->","summary":null,"htmlStringContent":"<!-- begin item 97b60a31-e2ed-44e6-ae92-a01f94252cd9 --><!-- begin field 445aa41a-63d7-465c-8d34-87f8baaf5437 --><ul><li>For comparison of the efficacy of progestogen-only injectables with other methods of contraception, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.<ul><li>When used perfectly (consistently and correctly), 0.2% of women will conceive within the first year of use due to method failure.</li><li>When used typically, 6% of women will conceive within the first year of use due to method failure or user failure.</li></ul></li></ul><!-- end field 445aa41a-63d7-465c-8d34-87f8baaf5437 --><!-- end item 97b60a31-e2ed-44e6-ae92-a01f94252cd9 -->","subChapters":[{"id":"12d3cb3c-7b2d-58e0-9e15-c0886e56f611","slug":"basis-for-recommendation-795","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2b5746b0-f716-4ee9-b9af-e49f2de89a4c --><h4>Basis for recommendation</h4><!-- end field 2b5746b0-f716-4ee9-b9af-e49f2de89a4c -->","summary":null,"htmlStringContent":"<!-- begin item 795cfd6e-eeaa-44ee-b323-2257c3d46ae4 --><!-- begin field 2de0e38e-7b5c-4627-9968-24c84220ba84 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>].</p><!-- end field 2de0e38e-7b5c-4627-9968-24c84220ba84 --><!-- end item 795cfd6e-eeaa-44ee-b323-2257c3d46ae4 -->","subChapters":[]}]},{"id":"44698f01-c5d1-56e3-b988-a4fe931e6ee5","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field c9f246f7-b5c9-4ca8-b8e7-aec0e067abfd --><h3>What follow up should I arrange for a woman using a progestogen-only injectable?</h3><!-- end field c9f246f7-b5c9-4ca8-b8e7-aec0e067abfd -->","summary":null,"htmlStringContent":"<!-- begin item a5177b5f-e952-4399-afc8-5bd9eee5bfd2 --><!-- begin field ef4a8166-8e73-469d-819f-6003c0124bde --><ul><li>At the follow up visit, when the woman attends for a repeat injection:<ul><li>Check her knowledge of what to do if she is <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#late-repeat\">late for injections</a>.</li><li>Address any issues or <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/#risks-adverse-effects\">adverse effects</a> she might have, such as weight gain and irregular menstrual bleeding.</li><li>Advise the woman to return if she experiences signs of infection at the site of the injection (for example redness, swelling, pain, or rash). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cellulitis-acute/\">Cellulitis - acute</a>.</li></ul></li><li>Review the woman every 2 years to assess the risks and benefits of the injection and to decide whether treatment can be continued.</li></ul><!-- end field ef4a8166-8e73-469d-819f-6003c0124bde --><!-- end item a5177b5f-e952-4399-afc8-5bd9eee5bfd2 -->","subChapters":[{"id":"bf84dbb0-b610-513e-b384-c6aac8716495","slug":"duration-of-use","fullItemName":"Duration of use","depth":4,"htmlHeader":"<!-- begin field 6c032f69-e25b-43f7-8c85-a6ce00bb2287 --><h4>How long can the progestogen-only injection be used for?</h4><!-- end field 6c032f69-e25b-43f7-8c85-a6ce00bb2287 -->","summary":null,"htmlStringContent":"<!-- begin item 7a609318-e754-4f7a-b340-a6ce00bb20c0 --><!-- begin field 912ff558-5350-4b84-8331-a6ce00bb2287 --><p><strong>Depot medroxyprogesterone acetate </strong>(Depo-Provera® or Sayana Press®)</p><ul><li>No maximum duration of use is suggested in the Summaries of Product Characteristics.</li><li>Review women using depot medroxyprogesterone acetate every 2 years to discuss the benefits and potential risks of continuing this method of contraception.</li><li>When the woman reaches 50 years of age, stop depot medroxyprogesterone acetate and switch to one of the following methods:<ul><li>A non-hormonal method of contraception (the copper intrauterine device or barrier methods).</li><li>An alternative hormonal method of contraception (the progestogen-only pill, the progestogen-only implant, or the levonorgestrel intrauterine system).</li></ul></li></ul><p><strong>Norethisterone enantate </strong>(Noristerat®)</p><ul><li>Norethisterone enantate is only licensed for up to two injections, given 8 weeks apart.</li></ul><!-- end field 912ff558-5350-4b84-8331-a6ce00bb2287 --><!-- end item 7a609318-e754-4f7a-b340-a6ce00bb20c0 -->","subChapters":[]},{"id":"68ab576a-0a3c-58ba-869b-f8729ffa1137","slug":"timing-of-repeat-injections","fullItemName":"Timing of repeat injections","depth":4,"htmlHeader":"<!-- begin field 01ce0363-cdb5-4a8c-937b-a6ce00bb14f7 --><h4>How often should I repeat the progestogen-only injection?</h4><!-- end field 01ce0363-cdb5-4a8c-937b-a6ce00bb14f7 -->","summary":null,"htmlStringContent":"<!-- begin item cef178cd-4518-4da6-a313-a6ce00bb130f --><!-- begin field 02b42a7f-b99b-40d0-bf02-a6ce00bb14f7 --><ul><li><strong>For Depo-Provera® </strong>(depot medroxyprogesterone acetate):<ul><li>Repeat the injection every 12 weeks.</li><li>However, if this is not possible, repeat injections can also be given up to 2 weeks early (every 10 weeks) or up to 2 weeks late (every 14 weeks).</li></ul></li><li><strong>For Sayana Press®</strong> (depot medroxyprogesterone acetate):<ul><li>Repeat the injection every 13 weeks.</li><li>However, if this is not possible, repeat injections can also be given up to 1 week late (every 14 weeks).</li></ul></li><li><strong>For Noristerat</strong><strong>® </strong>(norethisterone enantate):<ul><li>Repeat the injection after 8 weeks. <ul><li>Be aware that norethisterone enantate is licensed for up to two injections only, 8 weeks apart.</li></ul></li><li>However, if this is not possible, a repeat injection can also be given up to 2 weeks early (6 weeks apart) or up to 2 weeks late (10 weeks apart).</li></ul></li></ul><!-- end field 02b42a7f-b99b-40d0-bf02-a6ce00bb14f7 --><!-- end item cef178cd-4518-4da6-a313-a6ce00bb130f -->","subChapters":[]},{"id":"a3453c08-89cb-5fa7-92e7-0486e7aebfe6","slug":"basis-for-recommendation-878","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fb2236e1-807f-49be-807d-86dc86c9db7f --><h4>Basis for recommendation</h4><!-- end field fb2236e1-807f-49be-807d-86dc86c9db7f -->","summary":null,"htmlStringContent":"<!-- begin item 8787b40b-9fb3-40b9-94f7-96b0e287b2cf --><!-- begin field d307cb97-3893-455d-bf55-1f15ec823d83 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2014b</a>], <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">FSRH, 2010b</a>] and the manufacturers' Summaries of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-progestogen-only-methods/references/\">ABPI, 2016e</a>].</p><!-- end field d307cb97-3893-455d-bf55-1f15ec823d83 --><!-- end item 8787b40b-9fb3-40b9-94f7-96b0e287b2cf -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}